Skip to main content
    F

    Fractyl Health, Inc. Common Stock (GUTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.99
    +0.09 (+9.76%)

    Market Cap: $11.99M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fractyl Health, Inc. Common Stock (GUTS) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Fractyl Health, Inc. Common Stock reported EPS of -$1.39, above the -$1.59 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(8/11)
    Avg Surprise
    +7.72%
    Streak
    4 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$1.38
    Range-$1.76 - -$1.13
    7 analysts
    Revenue Consensus
    N/A
    RangeN/A
    7 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.89
    Range-$1.52 - -$0.25
    2 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.68+47.3%
    60d ago-$1.26+29.8%
    30d ago-$1.26+29.8%
    7d ago-$0.86-2.9%
    Current-$0.89
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    GUTS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    GUTS Earnings Call

    The latest GUTS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 11 quarters below that had an estimate, GUTS beat 8 and missed 3. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 121.88% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.39-$1.59-$1.68 - -$1.38+12.58%BeatN/A40 up, 2 downNov 12, 2026N/A
    Jun 30, 2026-$0.12-$0.15-$0.15 - -$0.11+20.00%BeatN/A63 up, 0 downAug 10, 2026N/A
    Mar 31, 2026$0.06-$0.41N/A+114.20%BeatN/A52 up, 1 downMay 12, 2026N/A
    Dec 31, 2025-$0.07-$0.18-$0.22 - -$0.14+61.11%BeatN/A50 up, 2 downMar 24, 2026N/A
    Sep 30, 2025-$0.71-$0.32-$0.38 - -$0.18-121.88%MissN/A51 up, 0 downNov 12, 2025N/A
    Jun 30, 2025-$0.57-$0.36-$0.38 - -$0.35-58.33%MissN/A30 up, 1 downAug 12, 2025N/A
    Mar 31, 2025-$0.49-$0.50-$0.53 - -$0.47+2.00%BeatN/A20 up, 0 downMay 13, 2025N/A
    Dec 31, 2024-$0.52-$0.42-$0.53 - -$0.34-23.81%MissN/A20 up, 1 downMar 3, 2025$3000
    Sep 30, 2024-$0.43-$0.50-$0.50 - -$0.50+14.00%BeatN/A10 up, 0 downNov 12, 2024$14000
    Jun 30, 2024-$0.36-$0.46N/A+21.74%BeatN/AN/AN/AAug 14, 2024$43000
    Mar 31, 2024-$0.17-$0.30N/A+43.33%BeatN/AN/AN/AApr 1, 2024$33000
    Last 11 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$1.52N/A
    Jun 30, 2026-$0.13N/A
    Sep 30, 2025-$2.29N/A
    Sep 30, 2024-$0.96N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,0009
    2026Q2Jun 30, 20265,32111
    2026Q1Mar 31, 20265,23810
    2025Q4Dec 31, 20255,31810
    2025Q3Sep 30, 20254,79011
    2025Q2Jun 30, 20254,8499
    2025Q1Mar 31, 20254,2438
    2024Q4Dec 31, 20244,9738

    2026Q3 Earnings Call

    Opening remarks

    Brian Luque Head of Investor Relations and Corporate Development Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lara Smith Weber, Chief Financial Officer. Before we begin, one change to our format: For the first time, we invited all of our shareholders to submit and vote on questions for management through Say by Robinhood. After our prepared remarks, I will read a selection of the most-voted shareholder questions, and then the operator will open the line to our covering analysts. Thank you to everyone who took part. During this call, we make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties and speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements, even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Harith.

    Harith Rajagopalan Chief Executive Officer Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing GLP-1s each month. Yet, of those who take GLP-1s, only 1 in 12 Americans remain on them for obesity at the end of 3 years. What happens for the 11 out of 12 who stop? On average, 85% of patients regain weight, and roughly two-thirds of the weight comes back within a year. That is a systemic pattern driven by biology, not an individual failure of willpower, and it doesn't have to be this way. So why does the weight come back? We believe the answer is in the gut. Modern unhealthy diets accelerate cellular aging in the gut. In plain terms, those changes make us more prone to obesity. And the aging gut may retain a metabolic memory that perpetuates disease. GLP-1 medicines have proven that dramatic weight loss is possible, but they neither reverse the underlying cellular aging causing obesity nor regenerate a healthy gut. They leave the underlying problem untouched. Revita aims to do both. It is designed to reset the gut's metabolic memory as a one-time outpatient procedure designed to ablate the damaged, unhealthy lining of the duodenum to allow healthier tissue to regenerate in its place. LASIK for obesity. It means the gut is now working with, not against, a patient's weight loss program.

    Frequently Asked Questions About GUTS

    Did GUTS beat earnings estimates last quarter?

    Yes. Fractyl Health, Inc. Common Stock reported EPS of -$1.39 for the quarter ended Sep 30, 2026, above the -$1.59 estimate, a 12.58% surprise.

    What EPS do analysts expect from GUTS next quarter?

    The consensus EPS estimate for Fractyl Health, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.38 from 7 analysts, with estimates from -$1.76 to -$1.13.

    How often does GUTS beat earnings estimates?

    Fractyl Health, Inc. Common Stock beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.73%.